

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Ravulizumab for treating generalised myasthenia gravis [ID4019]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A patient group commented that it is important to ensure that no patient has to travel excessive distances to receive the treatment given the level of disability that many will face.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Issues of healthcare implementation cannot be addressed in a technology appraisal. However the committee will consider whether its recommendations make it harder for groups with protected characteristics, including those with a disability, to access treatment.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name): Ross Dent

Date: 26/08/2022